BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

Outstanding capital return in final distribution for Australian Bioscience Fund I  Australia’s best performing biotech fund in recent years as per Cambridge Associates ratings 13 August 2014: AusBiotech Industry Spotlight here. Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% […]


7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]

BioScience Managers Banks on Growth in Anti-Infectives Market

Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK). AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven […]

Bioscience Managers Supports Bioxyne Decision on Transaction

International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]

Super Funds Urged To Consider Healthcare Sector For Exceptional Returns

.. IB Australian Bioscience Fund I outperforms ASX200AI by 72%  Delivers ~30% annual IRR* Melbourne, Australia 8 April  2013: A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the […]

BioScience Managers Expands Asia Pac Presence – Invests $3M in NZ Patient Monitoring Company

(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6. Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage […]

BioScience Managers Backs Bioxyne Move

BioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd. Following Bioxyne’s existing product HI-164OV failing to reach clinical trial endpoints last year, BioScience Managers, a 20+% shareholder in BXN, has been at the forefront of […]

Bioscience Managers Announces First Close on New Healthcare Fund

Top Decile[1] Fund Manager announces first close on second fund First closing at A$55m supported by Australian institutions IOOF provides $45m cornerstone Focused on clinical stage healthcare and life sciences firms First investment $3m into ASX Listed Avita (ASX.AVH) Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its […]

Australian Bioscience Fund I to invest in Sea Dragon Marine Oils

IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital (NZX.CLA) in conjunction with Claridge’s acquisition of SeaDragon Marine Oils. The subscription arrangement is conditional upon the satisfaction of a number of commercial conditions. The […]

Angiotech Founder Joins Union Medtech & Bioscience Managers’ Global Team

Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board. William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university.  […]